home / stock / ivevf / ivevf articles
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inven...
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety data The safet...
Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 3...
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of June 30, 2...
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive lice...
Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharma...
News, Short Squeeze, Breakout and More Instantly...
Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term. Cash runway extended...
Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3. Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a pat...
Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l’Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program a...